Loxo Oncology (NASDAQ:LOXO) CEO Joshua H. Bilenker sold 15,000 shares of the business’s stock in a transaction on Tuesday, May 15th. The shares were sold at an average price of $136.51, for a total transaction of $2,047,650.00. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Loxo Oncology opened at $167.53 on Friday, according to Marketbeat. The firm has a market cap of $4.23 billion, a PE ratio of -31.55 and a beta of 2.32. Loxo Oncology has a one year low of $138.92 and a one year high of $143.55.
Loxo Oncology (NASDAQ:LOXO) last released its quarterly earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01. During the same quarter in the previous year, the business earned ($0.96) EPS. sell-side analysts anticipate that Loxo Oncology will post 0.55 earnings per share for the current fiscal year.
A number of large investors have recently made changes to their positions in the stock. Millennium Management LLC grew its position in Loxo Oncology by 90.4% in the first quarter. Millennium Management LLC now owns 15,398 shares of the biopharmaceutical company’s stock worth $1,776,000 after acquiring an additional 7,312 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in Loxo Oncology during the first quarter valued at about $321,000. Rock Springs Capital Management LP boosted its position in Loxo Oncology by 2.1% during the first quarter. Rock Springs Capital Management LP now owns 316,500 shares of the biopharmaceutical company’s stock valued at $36,515,000 after buying an additional 6,500 shares during the period. UBS Group AG boosted its position in Loxo Oncology by 120.4% during the first quarter. UBS Group AG now owns 28,026 shares of the biopharmaceutical company’s stock valued at $3,233,000 after buying an additional 15,308 shares during the period. Finally, Lord Abbett & CO. LLC boosted its position in Loxo Oncology by 20.8% during the first quarter. Lord Abbett & CO. LLC now owns 666,771 shares of the biopharmaceutical company’s stock valued at $76,926,000 after buying an additional 114,963 shares during the period.
A number of brokerages have issued reports on LOXO. Zacks Investment Research cut shares of Loxo Oncology from a “buy” rating to a “hold” rating in a report on Wednesday, April 25th. Cann began coverage on shares of Loxo Oncology in a report on Wednesday, February 21st. They set an “outperform” rating and a $132.00 target price on the stock. JMP Securities set a $182.00 target price on shares of Loxo Oncology and gave the company a “buy” rating in a report on Thursday. William Blair reissued a “buy” rating on shares of Loxo Oncology in a report on Monday, April 16th. Finally, Morgan Stanley raised shares of Loxo Oncology from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $130.00 to $170.00 in a report on Monday, April 16th. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and three have issued a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $152.89.
About Loxo Oncology
Loxo Oncology, Inc, a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.
Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.